Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience

1. Romer, Alfred Sherwood; Parsons, Thomas S. The Vertebrate Body. Philadelphia:Holt-Saunders International; 1977.Search in Google Scholar

2. Mettlin C, Selenkas S, Natarajan N, et al. Beta-caroten, animal fats and prostate cancer risk: a case control study. Cancer 1989; 64: 605–612.10.1002/1097-0142(19890801)64:3<605::AID-CNCR2820640307>3.0.CO;2-ISearch in Google Scholar

3. Lumey LH, Pittman B, Wynder EL. Alcohol use and prostatae cancer in U.S. whites: no association in a confirmatory study. Prostate 1998; 36(4): 250–255.10.1002/(SICI)1097-0045(19980901)36:4<250::AID-PROS6>3.0.CO;2-JSearch in Google Scholar

4. Hellstrom WJG, ed.”Chapter 8: What is the prostate and what is its function?”. American Society of Andrology Handbook. San Francisco: American Society of Andrology; 1999.Search in Google Scholar

5. Shimizu H, Ross RK, Bernstein L, et al.Cancers of the prostate and breast among the Japanese and white immigrants in Los Angeles Country. Br J Cancer 1991; 63: 963–966.10.1038/bjc.1991.210Search in Google Scholar

6. Mettlin C. Recent developments in the epidemiology of prostate cancer. Eur JCancer 1997; 33(3): 340–347.10.1016/S0959-8049(97)89003-XSearch in Google Scholar

7. Merril RM, Weed DL, Feuer EJ. The lifetime risk of developing prostate cancer in white and black men. Cancer Epidemiol Biomarkers Prev 1997; 6(10): 763–768.Search in Google Scholar

8. Tsukise, A.; Yamada, K. “Complex carbohydrates in the secretory epithelium of the goat prostate”. The Histochemical Journal 16 1984; (3): 311–9.10.1007/BF01003614Search in Google Scholar

9. Mettlin C, Lee F, Drago J, et al. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67: 2949–63.10.1002/1097-0142(19910615)67:12<2949::AID-CNCR2820671202>3.0.CO;2-XSearch in Google Scholar

10. Carroll P, Coley C, McLeod D, et al. Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer. Urology 2001; 57: 217–31.10.1016/S0090-4295(00)00993-6Search in Google Scholar

11. Hayes RB, Brown LM, Schoenberg JB et al. Alcohol use and prostate cancer risk in US blacks and whites. Am J epidemiol 1996; 143(7): 692–697.10.1093/oxfordjournals.aje.a008802Search in Google Scholar

12. Emami N, Deperthes D, Malm J et al. Major role of human KLK14 in seminal clot liquefaction. J Biol Chem 2008; 283(28): 19561–9.10.1074/jbc.M801194200Search in Google Scholar

13. Boyle P, Maisonneuve P, Napalkov B. Incidence of prostate cancer Will double by the year 2030: The Argument For. Eur Urol 1996; 29(suppl 2): 3–9.10.1159/000473828Search in Google Scholar

14. Terris MK, Peehl DM. Human papilomavirus detection by polymerase chain reaction in benign and malignant prostate tissue is dependent on the primer set utilized. Urology 1997; 50(1): 150–156.10.1016/S0090-4295(97)00126-XSearch in Google Scholar

15. SvatekRS, KaramJA, RoehrbornCG, et al.: Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy.Clin Cancer Res. 2008; 14(11): 3362–336610.1158/1078-0432.CCR-07-4707Search in Google Scholar

16. Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998; 52: 195–207.10.1016/S0090-4295(98)00184-8Search in Google Scholar

17. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868–82.10.1093/jnci/95.12.868Search in Google Scholar

18. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004; 10: 3943–50.10.1158/1078-0432.CCR-03-0200Search in Google Scholar

19. Coleman MP, Esteve J, Damiecki P et al. Trends in Cancer Incidence and Mortality. Lyon: IARC Scientific Publication No.121; 1993.Search in Google Scholar

20. Boyle P. Prostate cancer 2000: evolution of an epidemic of unknown origin. In: Denis L, ed. Prostate cancer 2000. Heidelberg: Springer – Verlag, 1994: 5–11.10.1007/978-3-642-79178-9_3Search in Google Scholar

21. Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948–53.10.1001/jama.1993.03510080052031Search in Google Scholar

22. de Lamirande E., O’Flaherty C. Sperm activation: role of reactive oxygen species and kinases.Biochim Biophys Acta. 2008; 1784: 106–115.10.1016/j.bbapap.2007.08.024Search in Google Scholar

23. ParsonsJK. Modifiable risk factors for benign prostatic hiperplasia and lower urinary tract symptoms : new aproaches to old problems. J Urol 2007; 178(2): 395–401.10.1016/j.juro.2007.03.103Search in Google Scholar

24. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2): 71–96.10.3322/CA.2007.0010Search in Google Scholar

25. Brawer MK, Chetner MP, Beatie J, et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 841–52.10.1016/S0022-5347(17)37401-3Search in Google Scholar

26. Crawford ED, DeAntoni EP, Etzioni R, et al. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 1996; 47: 863–74.10.1016/S0090-4295(96)00061-1Search in Google Scholar

27. Draisma G, Etzioni R, Tsodikov A, et al.: Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 101; 374–383: 2009.10.1093/jnci/djp001272069719276453Search in Google Scholar

28. Hayes RB, Brown LM, Schoenberg JB et al. Alcohol use and prostate cancer risk in US blacks and whites. Am J epidemiol 1996;143(7): 692–697.10.1093/oxfordjournals.aje.a0088028651231Search in Google Scholar

29. Andriole GL, Levin DL, Crawford ED, et al.: Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst. 2005; 97(6): 433–43810.1093/jnci/dji06515770007Search in Google Scholar

30. Anglin IE, Glassman DT, Kyprianou N et al.: Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002; 5(2): 88–95 2002.10.1038/sj.pcan.450056112496995Search in Google Scholar

31. Coppola V, Musumeci M, Patrizii M, et al. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial–mesenchymal transition. Oncogene. 2013; 32(14): 1843–1853.10.1038/onc.2012.19422614007Search in Google Scholar

32. Filella X, Foj L. miRNAs as novel biomarkers in the management of prostate cancer. Clin Chem Lab Med. 2017; 55(5): 715–736.10.1515/cclm-2015-107326751899Search in Google Scholar

33. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007; 448: 595–599.10.1038/nature0602417671502Search in Google Scholar

34. Soller MJ, Isaksson M, Elfving P, et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer. 2006; 45: 717–719.10.1002/gcc.2032916575875Search in Google Scholar

35. Folini M, Gandellini P, Longoni N, et al. miR21: an oncomir on strike in prostate cancer. Mol Cancer. 2010; 9: 12.10.1186/1476-4598-9-12282365020092645Search in Google Scholar

36. Mehra R, Tomlins SA, Yu J, et al. Characterization of TMPRSS2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer. Cancer Res. 2008; 68: 3584–359010.1158/0008-5472.CAN-07-6154267716818483239Search in Google Scholar

37. Liu B, Gu X, Huang T, et al. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1. Oncology Reports Jan 2017; 37(1): 201–208.10.3892/or.2016.527728004109Search in Google Scholar

38. Pettersson A1, Graff RE, Bauer SR, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. Sep 2012; 21(9): 1497–509.10.1158/1055-9965.EPI-12-0042Search in Google Scholar

39. Kulda V, Topolcan O, Kucera R, et al. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer. Anticancer Research. Sep 2016; 36(9): 4787–4793.10.21873/anticanres.11037Search in Google Scholar

40. Saramäki O.R, Harjula A.E, Martikainen P.M, et al. TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis. Clin Cancer Res. Jun 2008; 14(11): 3395–3400.10.1158/1078-0432.CCR-07-2051Search in Google Scholar

41. Krstanoski Z, Kokalj Vokac N, Zagorac A, et al. TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.BMC UROL. 2016 Jul 4; 16(1): 35. doi: 10.1186/s12894-016-0160-8.10.1186/s12894-016-0160-8493276527377958Search in Google Scholar

42. Yılmaz O, Berber U, Okçelik S, et al.TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical pros-tatectomy specimens J Urol. 2016 Jun; 42(2): 60–63. doi: 10.5152/tud.2016.9476310.5152/tud.2016.94763485791827274888Search in Google Scholar

43. Noonan KL, North S, Bitting RL, et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013; 24(7): 1802–1807.10.1093/annonc/mdt13823585511Search in Google Scholar

44. Lapointe J, Kim YH, Miller MA, et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod. Pathol. 2007; 20: 467–473.10.1038/modpathol.3800759Search in Google Scholar

45. Cerveira N, Ribeiro FR, Peixoto A, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia. 2006; 8: 826–832.10.1593/neo.06427171593017032499Search in Google Scholar

46. Clark J, Merson S, Jhavar S, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007; 26: 2667–2673.10.1038/sj.onc.121007017043636Search in Google Scholar

47. Hermans KG, van Marion R, van Dekken H, et al. TMPRSS2:ERG fusion by translocation or inter-stitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 2006; 66: 10658–10663.10.1158/0008-5472.CAN-06-187117108102Search in Google Scholar

48. Iljin K, Wolf M, Edgren H, et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 2006; 66: 10242–10246.10.1158/0008-5472.CAN-06-198617079440Search in Google Scholar

49. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006; 66: 8337–8341.10.1158/0008-5472.CAN-06-148216951139Search in Google Scholar

50. Wang J, Cai Y, Ren C, et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 2006; 66: 8347–8351.10.1158/0008-5472.CAN-06-196616951141Search in Google Scholar

51. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007; 26: 4596–4599.10.1038/sj.onc.121023717237811Search in Google Scholar

52. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod. Pathol. 2007; 20: 538–544.10.1038/modpathol.3800769Search in Google Scholar

53. Nam RK, Sugar L, Wang Z, et al. Expression of TMPRSS2 ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol. Ther. 2007; 6: 40–45.10.4161/cbt.6.1.3489Search in Google Scholar

54. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J. Clin. Pathol. 2007; 60: 1238–1243.10.1136/jcp.2006.043810Search in Google Scholar

55. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008; 10: 177–188.10.1593/neo.07822224469318283340Search in Google Scholar

56. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer. 2008; 8: 497–511.10.1038/nrc2402Search in Google Scholar

57. Rubin MA. Targeted therapy of cancer: new roles for pathologists–prostate cancer. Mod. Pathol. 2008; 21(Suppl. 2): S44–S55.10.1038/modpathol.2008.1118437173Search in Google Scholar

58. Stuart RO, Wachsman W, Berry CC, et al. In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc. Natl Acad. Sci. USA. 2004; 101: 615–620.10.1073/pnas.253647910032719614722351Search in Google Scholar

59. Syed JS, Javier-Desloges J, Tatzel S, et al. Current management strategy for active surveillance in prostate cancer. Curr Oncol Rep. 2017; 19(2): 11.10.1007/s11912-017-0569-628220449Search in Google Scholar